Moderna Outlines Pregnancy Outcome Study Details For Its COVID-19 Shot

Vandana Singh
·1 min read

  • In a few days, Moderna Inc (NASDAQ: MRNA) will start a trial designed to evaluate pregnancy outcomes in women after receiving the Company's COVID-19 shot during their pregnancy.

  • According to an update posted on the ClinicalTrials.gov website, the trial will begin on July 22, targeting the enrollment of 1,000 participants.

  • The observational study with a 21-month follow-up period is expected to complete in January 2024.

  • During the period, the primary data from pregnant women and their healthcare providers will be collected for the study.

  • The Centers for Disease Control and Prevention recommended that pregnant females receive the messenger-RNA-based COVID-19 vaccines developed by Pfizer Inc (NYSE: PFE)/ BioNTech SE (NASDAQ: BNTX) and Moderna.

  • Also, Monday, Moderna announced a supply agreement with the government of Argentina for 20 million doses of its COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized.

  • Delivery will start from 1Q of 2022.

  • Price Action: MRNA shares are up 3.7% at $241.24 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.